NMDP research shows a high unmet need in transplant. Specific to allogeneic transplants, approximately 50 percent of eligible patients do not receive a transplant.
- Role of age and comorbidity: Patients can successfully receive a transplant later in life and with more comorbidities than previously. The Fred Hutch BMT program at SCCA offers more transplant options than ever before as reduced-intensity/non-myeloablative conditioning makes HCT suitable for older patients and those with comorbidities. In fact, the Fred Hutch BMT Program at SCCA does not limit HCT based on age alone.
- AML cytogenetic/molecular risk: American Society for Blood and Marrow Transplantation (ASBMT) and the National Marrow Donor Program (NMDP) guidelines show that many patients with intermediate-risk cytogenetic/molecular abnormalities benefit from transplant, yet many of these patients are not offered transplants.
- Expanding donor options: Nearly every patient can be matched with a donor because of alternative stem cell sources such as unrelated donors (including partially HLA-mismatched), haplo-identical (half-matched relative) donors, or umbilical cord blood. The Fred Hutch BMT Program at SCCA is a leader in this work.
- Timing of transplant: Patients transplanted earlier in the course of their disease have better overall survival than patients with advanced disease. As an example in AML is that when NMDP surveyed providers, they found that only 52 percent of AML patients are referred to BMT in CR1 (36 percent referred in CR2, 12 percent referred in CR3).
Doctors at the Fred Hutch Bone Marrow Transplant Program at Seattle Cancer Care Alliance (SCCA) have performed more than 15,000 bone marrow transplants — more than any other institution in the world.